Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol

INTRODUCTION: Chronic heart failure with reduced ejection fraction (HFrEF) treatment targets neurohormonal inhibition; however, our experimental observations and the recent clinical evidence in myocardial infarction and heart transplant patients support the anti-inflammatory pathway as a potential n...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Trujillo, Luis, Jerjes-Sanchez, Carlos, Rodriguez, David, Panneflek, Jathniel, Ortiz-Ledesma, Claudia, Garcia-Rivas, Gerardo, Torre-Amione, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475246/
https://www.ncbi.nlm.nih.gov/pubmed/30918029
http://dx.doi.org/10.1136/bmjopen-2018-022826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475246/
https://www.ncbi.nlm.nih.gov/pubmed/30918029
http://dx.doi.org/10.1136/bmjopen-2018-022826

Ejemplares similares